OMPdecase: A Potential Drug Target and Biomarker (G7372)

Target Name: UMPS

NCBI ID: G7372

UMPS

OMPdecase: A Potential Drug Target and Biomarker

University of Massachusetts Personalized Medicine (UMPS) is a research organization that focuses on developing innovative solutions for healthcare through the use of personalized medicine. One of their main research areas is OMPdecase, which is a drug target or biomarker that could be used to develop new treatments for various diseases.

OMPdecase is a protein that is expressed in many different tissues throughout the body, including the brain, heart, and kidneys. It is involved in a number of different processes in the body, including blood clotting, inflammation, and cell signaling.UMPS researchers have identified a potential drug target for OMPdecase, which involves using small molecules to inhibit the activity of the protein.

The drug target for OMPdecase is located on the surface of OMPdecase, which is a protein that is involved in many different processes in the body. The researchers have identified a potential drug that could bind to the protein and inhibit its activity. This drug could potentially be used to treat a number of different diseases, including heart disease, cancer, and neurological disorders.

OMPdecase is also a potential biomarker for several different diseases. The researchers have used a variety of techniques to identify differentially expressed genes in the RNA of OMPdecase-deficient mice, which they believe may be involved in the development and progression of certain diseases. They are currently testing these genes as potential biomarkers for a number of different diseases, including cancer, heart disease, and neurological disorders.

In addition to its potential drug and biomarker applications, OMPdecase is also an interesting candidate for a potential therapeutic target for a number of different diseases. The researchers have identified a number of different ways in which OMPdecase may be involved in the development and progression of certain diseases, including blood clotting, inflammation, and cell signaling. They are currently exploring these potential applications in more detail in order to understand the full potential of OMPdecase as a drug or biomarker.

Overall, OMPdecase is a protein that is expressed in many different tissues throughout the body, and the researchers at UMPS have identified a potential drug target for it. Further research is needed to fully understand the full potential of OMPdecase as a drug or biomarker, and to explore its potential applications in the treatment of a variety of different diseases.

Protein Name: Uridine Monophosphate Synthetase

Functions: Bifunctional enzyme catalyzing the last two steps of de novo pyrimidine biosynthesis, orotate phosphoribosyltransferase (OPRT), which converts orotate to orotidine-5'-monophosphate (OMP), and orotidine-5'-monophosphate decarboxylase (ODC), the terminal enzymatic reaction that decarboxylates OMP to uridine monophosphate (UMP)

The "UMPS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UMPS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets